JP2015511603A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511603A5 JP2015511603A5 JP2015500523A JP2015500523A JP2015511603A5 JP 2015511603 A5 JP2015511603 A5 JP 2015511603A5 JP 2015500523 A JP2015500523 A JP 2015500523A JP 2015500523 A JP2015500523 A JP 2015500523A JP 2015511603 A5 JP2015511603 A5 JP 2015511603A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- wild type
- substitution
- acid position
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/418,242 | 2012-03-12 | ||
| US13/418,242 US9175331B2 (en) | 2010-09-10 | 2012-03-12 | Inhibitors of human EZH2, and methods of use thereof |
| PCT/US2013/030565 WO2013138361A1 (en) | 2012-03-12 | 2013-03-12 | Inhibitors of human ezh2, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017245743A Division JP6592071B2 (ja) | 2012-03-12 | 2017-12-22 | ヒトｅｚｈ２の阻害剤およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511603A JP2015511603A (ja) | 2015-04-20 |
| JP2015511603A5 true JP2015511603A5 (https=) | 2016-05-12 |
| JP6321619B2 JP6321619B2 (ja) | 2018-05-09 |
Family
ID=47913638
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500523A Active JP6321619B2 (ja) | 2012-03-12 | 2013-03-12 | ヒトｅｚｈ２の阻害剤およびその使用方法 |
| JP2017245743A Active JP6592071B2 (ja) | 2012-03-12 | 2017-12-22 | ヒトｅｚｈ２の阻害剤およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017245743A Active JP6592071B2 (ja) | 2012-03-12 | 2017-12-22 | ヒトｅｚｈ２の阻害剤およびその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP2825161B1 (https=) |
| JP (2) | JP6321619B2 (https=) |
| KR (4) | KR102267502B1 (https=) |
| CN (2) | CN104540500B (https=) |
| AU (4) | AU2013232229B2 (https=) |
| CA (2) | CA2867282C (https=) |
| DK (1) | DK2825161T3 (https=) |
| ES (1) | ES2718900T3 (https=) |
| HU (1) | HUE042271T2 (https=) |
| PL (1) | PL2825161T3 (https=) |
| PT (1) | PT2825161T (https=) |
| RU (2) | RU2704445C2 (https=) |
| TR (1) | TR201904660T4 (https=) |
| WO (1) | WO2013138361A1 (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011160206A1 (en) | 2010-06-23 | 2011-12-29 | Morin Ryan D | Biomarkers for non-hodgkin lymphomas and uses thereof |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| US9394283B2 (en) | 2012-04-13 | 2016-07-19 | Epizyme, Inc. | Salt form of a human histone methyltransferase EZH2 inhibitor |
| SG10201608579UA (en) * | 2012-04-13 | 2016-12-29 | Epizyme Inc | Combination therapy for treating cancer |
| CA2884848C (en) * | 2012-09-28 | 2017-08-22 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| PE20150887A1 (es) | 2012-10-15 | 2015-06-04 | Epizyme Inc | Compuestos de benceno sustituidos |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| KR102142177B1 (ko) | 2013-10-16 | 2020-08-07 | 에피자임, 인코포레이티드 | Ezh2 억제용 하이드로클로라이드 염 형태 |
| EP3057594A4 (en) * | 2013-10-18 | 2017-06-07 | Epizyme, Inc. | Method of treating cancer |
| CA2931263A1 (en) | 2013-12-06 | 2015-06-11 | Epizyme, Inc. | Combination therapy for treating cancer |
| US20160361309A1 (en) * | 2014-02-26 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
| IL285201B2 (en) * | 2014-06-17 | 2024-05-01 | Epizyme Inc | EZH2 inhibitors for the treatment of lymphoma |
| EP3158086B1 (en) | 2014-06-19 | 2021-03-24 | Memorial Sloan-Kettering Cancer Center | Biomarkers for response to ezh2 inhibitors |
| IL310279A (en) * | 2014-10-16 | 2024-03-01 | Epizyme Inc | Method for treating cancer |
| WO2016073956A1 (en) | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| HUE062159T2 (hu) * | 2014-11-17 | 2023-10-28 | Epizyme Inc | Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal |
| UY36462A (es) | 2014-12-23 | 2016-07-29 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos |
| WO2016172332A1 (en) * | 2015-04-22 | 2016-10-27 | The University Of North Carolina At Chapel Hill | A novel compound for the treatment of ewing sarcoma and high-throughput assays for identifying small molecules that modulate aberrant chromatin accessibility |
| EP3307713A4 (en) | 2015-06-10 | 2019-01-23 | Epizyme, Inc. | EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA |
| KR20180042356A (ko) | 2015-08-24 | 2018-04-25 | 에피자임, 인코포레이티드 | 암 치료 방법 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| JP7013369B2 (ja) * | 2015-09-25 | 2022-02-15 | エピザイム，インコーポレイティド | Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法 |
| EP3371601A1 (en) | 2015-11-05 | 2018-09-12 | Epizyme Inc | Flow cytometry for monitoring histone h3 methylation status |
| JP7493304B2 (ja) * | 2016-04-22 | 2024-05-31 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｅｚｈ２インヒビターおよびそれらの使用 |
| WO2017201585A1 (en) * | 2016-05-26 | 2017-11-30 | Genea Ip Holdings Pty Ltd | Modulators of dux4 for regulation of muscle function |
| WO2017210395A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| EP3471830A4 (en) | 2016-06-17 | 2020-02-26 | Epizyme Inc | EZH2 INHIBITORS TO TREAT CANCER |
| EP3472166A1 (en) | 2016-06-20 | 2019-04-24 | Novartis AG | Imidazopyrimidine compounds useful for the treatment of cancer |
| ES2975263T3 (es) | 2016-06-20 | 2024-07-04 | Novartis Ag | Formas cristalinas de un compuesto triazolopirimidínico |
| WO2017221092A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| CN109843870A (zh) | 2016-10-19 | 2019-06-04 | 星座制药公司 | Ezh2抑制剂的合成 |
| AU2017351638A1 (en) | 2016-10-26 | 2019-06-13 | Genea Biocells USA (Holdings), Inc. | Improved generation of muscle lineage cells and therapeutic uses thereof |
| WO2018086592A1 (zh) * | 2016-11-11 | 2018-05-17 | 上海海雁医药科技有限公司 | 4,5,6-三取代吲唑类衍生物、其制法与医药上的用途 |
| CN106963765B (zh) * | 2017-03-28 | 2020-04-07 | 上海交通大学医学院附属第九人民医院 | Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用 |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP3630080A4 (en) | 2017-06-02 | 2021-03-10 | Epizyme, Inc. | USE OF EZH2 INHIBITORS TO TREAT CANCER |
| MX2020001875A (es) | 2017-08-18 | 2020-07-29 | Tragara Pharmaceuticals Inc | Forma polimorfica de tg02. |
| WO2019050924A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | POLY THERAPY FOR THE TREATMENT OF CANCER |
| WO2019204998A1 (zh) * | 2018-04-25 | 2019-10-31 | 北京肿瘤医院 | Ezh2抑制剂在治疗粘膜型黑色素瘤中的应用 |
| WO2019233285A1 (en) * | 2018-06-03 | 2019-12-12 | Chen Wen Pin | Method for treating non-compaction cardiomyopathy |
| EP3831822A4 (en) * | 2018-07-27 | 2022-03-23 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | POLY-SUBSTITUTED BENZENE COMPOUND, PROCESS OF MANUFACTURE AND USE THEREOF |
| EP3958854B1 (en) | 2019-04-22 | 2025-06-04 | University of Pittsburgh - of The Commonwealth System of Higher Education | Tg02 for use in treating gliomas in pediatric subjects |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
| CN113024516B (zh) * | 2021-03-29 | 2022-05-17 | 中国药科大学 | 双靶点parp/ezh2抑制剂、制备方法及用途 |
| EP4392034A1 (en) | 2021-08-25 | 2024-07-03 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of ezh2 inhibitors for the treatment of aortic valve stenosis |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CN119143880A (zh) * | 2024-09-20 | 2024-12-17 | 上海交通大学医学院附属第九人民医院 | 抗ezh2蛋白抗体及其应用 |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| EP1765994B1 (en) | 2004-06-01 | 2009-11-18 | The University of North Carolina at Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
| ES2324435B1 (es) * | 2005-10-27 | 2010-05-31 | Fundacion Para El Estudio De La Hematologia Y Hemoterapia De Aragon (Fehha) | Procedimiento y dispositivo de analisis in vitro de mrna de genes implicados en neoplasias hematologicas. |
| WO2008101118A2 (en) * | 2007-02-14 | 2008-08-21 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates |
| WO2009006577A2 (en) * | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| WO2009124137A2 (en) * | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| WO2012005805A1 (en) | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
| JP5864546B2 (ja) | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インダゾール |
| EA023788B1 (ru) | 2010-05-07 | 2016-07-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Производные индола и фармацевтические композиции на их основе |
| BR112013005806B1 (pt) * | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| JO3363B1 (ar) * | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| CA2850570A1 (en) * | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
-
2013
- 2013-03-12 RU RU2014141045A patent/RU2704445C2/ru active
- 2013-03-12 KR KR1020147028560A patent/KR102267502B1/ko not_active Expired - Fee Related
- 2013-03-12 TR TR2019/04660T patent/TR201904660T4/tr unknown
- 2013-03-12 CN CN201380024734.7A patent/CN104540500B/zh active Active
- 2013-03-12 KR KR1020227034498A patent/KR102587175B1/ko active Active
- 2013-03-12 KR KR1020217018417A patent/KR102453519B1/ko active Active
- 2013-03-12 CA CA2867282A patent/CA2867282C/en active Active
- 2013-03-12 PL PL13711265T patent/PL2825161T3/pl unknown
- 2013-03-12 WO PCT/US2013/030565 patent/WO2013138361A1/en not_active Ceased
- 2013-03-12 CN CN201910052279.0A patent/CN110420327B/zh active Active
- 2013-03-12 EP EP13711265.2A patent/EP2825161B1/en active Active
- 2013-03-12 EP EP18214827.0A patent/EP3536314A1/en not_active Withdrawn
- 2013-03-12 KR KR1020237033924A patent/KR20230145531A/ko not_active Ceased
- 2013-03-12 JP JP2015500523A patent/JP6321619B2/ja active Active
- 2013-03-12 HU HUE13711265A patent/HUE042271T2/hu unknown
- 2013-03-12 RU RU2019132222A patent/RU2019132222A/ru unknown
- 2013-03-12 AU AU2013232229A patent/AU2013232229B2/en not_active Ceased
- 2013-03-12 ES ES13711265T patent/ES2718900T3/es active Active
- 2013-03-12 DK DK13711265.2T patent/DK2825161T3/en active
- 2013-03-12 PT PT13711265T patent/PT2825161T/pt unknown
- 2013-03-12 CA CA3177515A patent/CA3177515A1/en active Pending
-
2017
- 2017-12-22 JP JP2017245743A patent/JP6592071B2/ja active Active
-
2018
- 2018-02-19 AU AU2018201176A patent/AU2018201176A1/en not_active Abandoned
-
2019
- 2019-10-17 AU AU2019250181A patent/AU2019250181A1/en not_active Abandoned
-
2021
- 2021-04-07 AU AU2021202119A patent/AU2021202119A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511603A5 (https=) | ||
| JP2018083821A5 (https=) | ||
| RU2014141045A (ru) | Ингибиторы ezh2 человека и способы их применения | |
| IL258544A (en) | Combined treatment for cancer | |
| AR112816A2 (es) | Compuestos que inhiben el enlace de la proteína smac al inhibidor de proteínas de apoptosis (iap) | |
| IN2014KN01714A (https=) | ||
| IN2014KN01716A (https=) | ||
| EP4417256A3 (en) | Materials and methods for improving lung function | |
| EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| NZ780183A (en) | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains | |
| EA201300322A1 (ru) | Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина | |
| MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| EA201390144A1 (ru) | Конъюгаты терапевтический пептид-полимер, частицы, композиции и связанные с ними способы | |
| JP2016522212A5 (https=) | ||
| PH12013502178B1 (en) | Compositions relating to a mutant clostridium difficile toxin and methods thereof | |
| PE20140133A1 (es) | Nuevas proteinas de union a antigenos | |
| NO20081427L (no) | Alfa2c-adrenoreseptoragonister | |
| MX2017000083A (es) | Compuestos de platino, composiciones y usos de estos. | |
| MX385575B (es) | Uso de moléculas de ligación a semaforina-4d para el tratamiento de aterosclerosis. | |
| AR071733A1 (es) | Terapia combinada de un anticuerpo anti-cd20 tipo ii con un inhibidor de proteasoma | |
| EA201591752A1 (ru) | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака | |
| JP2016508504A5 (https=) | ||
| EA201100072A1 (ru) | Новые композиции и способы | |
| MX391136B (es) | FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO |